Dr. Garcia Advances Aqualung Therapeutics to Human Clinical Trials

News Release Date: 
Friday, January 28, 2022

University of Arizona pulmonologist and CEO and founder of Aqualung Therapeutics, Joe G.N. "Skip" Garcia, MD, recently closed on a major investment that will help advance his new lung inflammation treatment to human clinical trials. The drug, a monoclonal antibody known as ALT-100, will work to reduce lung inflammation and poor health outcomes from various respiratory diseases.

Click here to read the full article about Dr. Garcia. 

Event Date: 
Friday, January 28, 2022 (All day)